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activation pathway. On the contrary, anti-inflammatory
agents such as interleukin (IL)-4 and glucocorticoids
were shown to inhibit expression of proinflammatory
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cytokines by macrophages, and this finding was inter-Freie UniversitaÈ t Berlin
preted as indicative of macrophage deactivation. MoreHindenburgdamm 30
recently, however, IL-4 and glucocorticoids were foundD-12200 Berlin
to induce increased expression of the macrophage man-Germany
nose receptor and to enhance the capacity for endocy-
tosis and antigen presentation of macrophages. Since
this was proof against mere deactivation of macro-Tvn enantivn h wysi§ glixetai kai ek toytvn apotelei
phages by anti-inflammatory agents, Gordon and col-to symφvnon.
leagues instead introduced the concept of alternativeNature strives for the opposite and from it generates
immunologic activation of macrophages (Stein et al.,consonance.
1992). Evidence has now accumulated which indicatesÐHerakleitos
that alternatively activated macrophages express a spe-
cial set of molecules enabling them to actively partici-
pate in anti-inflammatory processes, tolerance induc-
In the course of inflammatory reactions, proinflamma- tion, and healing. Recently, dendritic cells known as
tory mechanisms are most important to guarantee elimi- specialized antigen-presenting cells (APC) supporting
nation of the causative infectious, toxic, or allergenic Th1 differentiation have also been shown to undergo
agents. It is mandatory, however, that inflammatory pro- alternative activation under certain conditions. Here we
cesses, once induced, do not escalate but are again revisit Gordon's concept of alternative activation of APC
downregulated to allow healing. Therefore, proinflam- and show that it fits well with what is known as ªsup-
matory and anti-inflammatory mechanisms must be acti- pressiveº functions of APC (Figure 1).
vated spatially and temporally in a finely tuned manner.
The inflammatory processes in sepsis are a good exam- Molecular Repertoire of Alternatively
ple for such a balanced interplay. Here, the causative Activated Macrophages
agent is a microbial agent; however, massive secretion Alternative activation of macrophages may be induced
of cytokines such as interleukin (IL)-1 or tumor necrosis by IL-4 and glucocorticoids as well as by other cytokines
factor (TNF)-a actually mediates the detrimental devel- such as IL-10, IL-13, and transforming growth factor
(TGF)-b, with similar effects. Alternatively activated macro-opments. Via neuroinflammatory interactions, the septic
phages express phenotypic and molecular characteris-organism tries to counteract the effects of these proin-
tics that differ considerably from those of classicallyflammatory cytokines; finally, glucocorticoids are syn-
activated macrophages. Regulation and expression ofthesized and secreted and may exert their pleiotropic
inflammation-associated molecules and genes in mac-anti-inflammatory effects (Wilckens and De Rijk, 1997).
rophages is regulated antagonistically by IL-4 and IFNg,In addition, inflammatory diseases and allergies may not
i.e., alternative macrophage molecules are induced byonly be due to an aberrant overwhelming proinflamma-
IL-4 and inhibited by IFNg, while classical macrophagetory reaction, but they can also be caused by dysfunc-
molecules are induced by IFNg and inhibited by IL-4tion or failure of anti-inflammatory control mechanisms.
(Table 1). Alternatively activated macrophages preferen-This notion was very recently confirmed by the finding
tially express the receptors of innate immunity withthat certain mutations in a novel anti-inflammatory mole-
broad specificity for foreign antigens such as the macro-cule of bronchial epithelium (CC16) are associated with
phage mannose receptor (Stein et al., 1992), the b-glu-a tremendous increase in the risk of developing asthma
can-receptor (Mosser and Handman, 1992), scavenger(Laing et al., 1998). Interestingly, expression of CC16
receptor type I (Geng and Hansson, 1992), and CD163,strongly inhibits both production and biologic activity
a member of the scavenger receptor cysteine-rich familyof interferon (IFN)-g. Thus, proinflammatory reactions
(HoÈ gger et al., 1998). Despite this enhanced capacityare closely interconnected with counter-regulatory anti-
for phagocytosis, alternatively activated macrophages
inflammatory pathways.
do not exert enhanced killing functions towards mi-
In the regulation of immune-mediated as well as non- crobes. NO production, for example, is counteracted in
specific inflammation, antigen-presenting cells such as alternatively activated macrophages by enhanced ex-
mononuclear phagocytes and dendritic cells play a ma- pression of arginase, competing with NO synthases for
jor role. In the past, research in inflammation biology has L-arginine as its substrate (Munder et al., 1998). Simi-
focused on the proinflammatory actions of mononuclear larly, O2 production is suppressed in alternatively acti-
phagocytes including phagocytosis, antigen processing, vated macrophages (Becker and Daniel, 1990). Thus,
antigen presentation, T cell activation, and cytokine se- alternatively activated macrophages seem to be first-
cretion. IFNg and bacterial lipopolysaccharides were iden- line defense cells that need not mount a strong Th1
tified as the major mediators of this classical macrophage immune response in order to function successfully.
In addition, alternatively activated macrophages ex-
hibit enhanced expression levels of MHC class II mole-* To whom correspondence should be addressed (e-mail: goerdt@
zedat.fu-berlin.de). cules such as HLA-DR and HLA-DQ, indicating that they
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Figure 1. Differentiation of Alternatively Activated APC
are prepared for effective antigen presentation. With protein (MIP)-1a (Cheung et al., 1990; Standiford et al.,
1993; Bonder et al., 1998). Secondly, alternatively acti-respect to immunoglobulin receptors, alternatively acti-
vated macrophages display cell surface expression of vated macrophages are associated with a high degree
of vascularization in vivo and seem to be angiogenic inthe low-affinity Fce receptor (CD23); however, they do
not express any of the three species of Fcg receptors vitro (Goerdt et al., 1993b; Kodelja et al., 1997). Further-
more, phagocytosis of apoptotic cells leads to alterna-(Becker and Daniel, 1990). Thus, it seems that alterna-
tively activated macrophages may be able both to in- tive activation and inhibition of proinflammatory cyto-
kine secretion in macrophages in an autocrine/paracrineduce differentiation of naive T cells into antigen-specific
T helper cells, presumably of the Th2 type, and to exert manner (Fadok et al., 1998). Thus, alternatively activated
macrophages are strategically well located and wellTh2-associated effector functions (Cua and Stohlman,
1997). equipped to substantially contribute to healing in sub-
siding inflammatory reactions.In order to identify alternatively activated macro-
phages in vivo, monoclonal antibodies specific for al-
ternatively activated macrophages have been used, in- Suppressive Functions of Alternatively
Activated Macrophagescluding monoclonal antibody RM3/1 directed against a
glucocortiocid-inducible splice variant of the scavenger Immunosuppressive functions of macrophages have
been first described by Herberman and colleagues in thereceptor CD163 (HoÈ gger et al., 1998) and a monoclonal
antibody against MS-1 high molecular weight protein
(Goerdt et al., 1991; Walsh et al., 1991). In the healthy
Table 1. Molecular Repertoire of Alternatively versus Classicallyorganism, alternatively activated macrophages are pref-
Activated Macrophageserentially found in normal placenta and lung, where they
function to protect the respective organ from unwanted Alternative Classical
Activationa Activationinflammatory or immune reactions (Mues et al., 1989).
Alternatively activated macrophages were also identi- Cytokines IL-1R antagonist IL-1
fied during the healing phase of acute inflammatory re- IL-10 IL-6
actions, in chronic inflammatory diseases such as rheu- IL-12
TNFamatoid arthritis and psoriasis, and in wound healing
Chemokines DC-CK1/AMAC-1 MIP-1atissue (Goerdt et al., 1993a; Szekanecz et al., 1994;
Immune receptors FceRII (CD23s) FcgRI (CD64)Djemadji-Oudjiel et al., 1996). This distribution pattern
Mph mannose R FcgRII (CD32)
suggests that alternatively activated macrophages may Scavenger RI FcgRIII (CD16)
participate in the three phases of healing, i.e., down- b-glucan R
regulation of inflammation, angiogenesis, and elimina- CD163 (RM3/1)
Killer molecules Arginase NO, iNOStion of tissue debris. With respect to downregulation of
O2inflammation, alternatively activated macrophages are
characterized by expression and synthesis of anti-inflam- a Regulation and expression of inflammation-associated macro-
phage molecules and genes are regulated antagonistically by IL-4matory cytokines such as IL-10 and IL-1 receptor antag-
and IFNg, i.e., alternative macrophage molecules are induced byonist (Fenton et al., 1992; Schebesch et al., 1997); they
IL-4 and inhibited by IFNg, while classical macrophage moleculeslack expression of proinflammatory cytokines such as
are induced by IFNg and inhibited by IL-4.
IL-1, TNFa, IL-6, IL-12, and macrophage inflammatory
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mid-1970s (Oehler et al., 1977). Several lines of evidence APC and a specific T cell as a prerequisite to T cell
indicate today that alternatively activated macrophage activation, expansion, and differentiation. However, ex-
and suppressor macrophage populations may at least pression of DC-CK1 in alternatively activated macro-
partially overlap. Placental macrophages, protecting the phages as well as in dendritic cells indicates that DC-
immunologically privileged embryo, and alveolar macro- CK1 itself may not determine whether specific immunity
phages, protecting the lung from unwanted environmen- or tolerance is induced; other molecular and phenotypic
tally induced inflammation, are the prototype naturally traits of the particular APC may also be involved.
occurring suppressor macrophages (Chang et al., 1993).
The suppressive effectivity of alveolar macrophages is
Modulation of Granuloma Immunity by Alternativelyso strong that dendritic cell antigen presenting functions
Activated Suppressor Macrophagesin the lung may be totally suppressed (Holt et al., 1988).
A good example of the balancing functions of alternativelyBoth placental and alveolar macrophages have been
activated suppressor macrophages in inflammatory re-shown to be typical alternatively activated macrophage
actions is provided by various models of granuloma forma-populations (Mues et al., 1989; Kodelja et al., 1998). With
tion. During the initiation phase of a granuloma, first-linerespect to experimentally derived suppressor macro-
defense tissue macrophages and other injured cellularphages, circumstantial evidence also indicates a close
tissue components secrete proinflammatory cytokinesrelationship to alternatively activated macrophages. Ex-
(IL-1, TNFa) and chemokines (MIP-1a), activating endo-perimentally derived suppressor macrophages have
thelial cells and attracting blood-derived macrophagesbeen preferentially investigated using antigen-indepen-
to the lesion. These early lesional macrophages thendent processes in tumor-bearing animals or during cer-
start to synthesize granuloma initiation factors, amongtain infections (Chang et al., 1988; Saha et al., 1994).
them homologs of the immunophilin gene family. In theAntigen-specific suppressive actions of macrophages
phase of immune modulation, T cells secreting cyto-have also been reported (Kirschmann et al., 1994). In
kines along the lines defined by the Th1 and Th2 dichot-these model systems, IFNg, the classical macrophage
omy induce disease susceptibility or resistance. Inactivating cytokine, has been shown to directly inhibit
schistosomiasis (Stadecker and Villanueva, 1994), forsuppressor macrophage activity (Schmidt Pak et al.,
example, rejection of eggs is primarily induced by large1995). Vice versa, alternatively activated macrophages
granulomas and is accompanied by a dominant Th1in vitro actively inhibit mitogen-induced proliferation of
immune response. During the course of the disease, theperipheral blood lymphocytes and CD41 T cells (Sche-
newly developing granulomas are smaller and lack abesch et al., 1997). These findings convincingly confirm
prominent T cell component. These late granuloma mac-that alternative activation generates immunosuppres-
rophages strongly express IL-10 and induce clonal an-sive macrophage populations.
ergy in schistosoma egg antigen-specific Th1 cells whileBesides the well known suppressive macrophage me-
supporting schistosoma egg antigen-specific Th2 cells.diators, i.e., PGE2 and lipocortin I, macrophage-derived
The Th1-suppressive activity of these granuloma macro-IL-10 and TGFb have been shown to exert downmodu-
phages is so intense that they are even effective aslating and anti-inflammatory effects. Other cytokines
with suppressive activity such as IL-16 and monoclonal efferent suppressor macrophages in preinfected synge-
nonspecific suppressor factor (MNSF)-b have not been neic recipients (Villanueva et al., 1994). Thus, alterna-
shown to be expressed by macrophages (Nakamura et tively activated macrophages might also act in alleviat-
al., 1995), while ubiquitin cross-reactive protein (UCRP), ing disease activity or inducing tolerance in autoimmune
which, like MNSFb, belongs to the ubiquitin gene super- and allergic diseases despite established sensitization.
family, is expressed upon classical activation. Since the
proinflammatory cytokine macrophage migration inhibi-
Induction of Tolerance by Alternatively Activatedtory factor (MIF) may also be expressed by alternatively
Suppressor Macrophagesactivated macrophages (Calandra et al., 1995), it seems
UVB-induced contact tolerance is another excellentthat proinflammatory and anti-inflammatory actions are
model for functional integration of all facets of suppres-finely balanced in either activation pathway. This may
sive actions of alternatively activated macrophages. Con-hold true as well for a novel b-chemokine, dendritic cell-
tact tolerance is a state of unresponsiveness to epicuta-derived CC-chemokine (DC-CK)1 (Adema et al., 1997),
neously applied facultative contact allergens that iswhich is also named alternative macrophage activation
thought to represent the physiological reaction to theassociated CC-chemokine (AMAC)-1 (Kodelja et al., 1998),
environmental allergen thread. Contact tolerance isthat has recently been cloned from IL-4-treated antigen-
maintained by continuous contact with low-dose anti-presenting cells. This new chemokine is highly homolo-
gen or by UVB irradiation. While the APC mediating low-gous to MIP-1a. In contrast to MIP-1a, which is inducible
dose contact tolerance are still elusive, UVB-inducedby classical macrophage mediators and is inhibited by
contact tolerance has been shown to be mediated byIL-4 and glucocorticoids, its expression is specifically
alternatively activated macrophages (Stevens et al.,induced by alternative macrophage mediators such as
1995). UVB irradiation induces Langerhans cells to emi-IL-4, IL-13, and IL-10 and is inhibited by IFNg. In vivo,
grate from the epidermis into the dermis and further onalveolar macrophages, the prototype suppressor mac-
to the regional lymph nodes. Subsequently, the epider-rophages, and some lymphoid dendritic cells express
mis is repopulated by CD361CD11b1CD1a2 macro-DC-CK1, while the prototype dendritic cells, i.e., epider-
phages that express excessive amounts of IL-10, as wellmal Langerhans cells, do not. Functionally, it has been
as TGFb, but lack IFNa and -b (Knop et al., 1987). Byshown that DC-CK1 preferentially attracts naive CD41
secreting DC-CK1/AMAC-1, these UVB-induced alter-T cells. Thus, DC-CK1 is a chemokine that may be in-
volved in bringing together an alternatively activated natively activated macrophages may attract CD81 naive
Immunity
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Figure 2. Induction of Contact Tolerance by
Alternatively Activated APC
T cells that are induced to differentiate into tolerogenic mediators of alternative activation are IL-4 and gluco-
corticoids as well as IL-10. Functionally, alternativelyCD81 T cells secreting Th2-associated cytokines such
as IL-4 and IL-10 (Tc2 cells) (Baadsgaard et al., 1988; activated APC are important players in downmodulating
inflammation and immunity. Alveolar and placental mac-Steinbrink et al., 1996 ). Differentiation of Tc2 cells is
dependent on CD41 T cells and is mediated by their rophages are typical examples of naturally occuring,
alternatively activated macrophages; they representIL-2 production (Baadsgaard et al., 1988; Desvignes et
al., 1996). IL-2-producing T helper cells are induced by first-line defense cells that, if they function successfully,
need not mount a strong Th1 immune response. Instead,alternatively activated macrophage-derived TGFb; how-
ever, these T helper cells are defective in IL-2 receptor alternatively activated macrophages exert Th2-associ-
ated effector functions characterized by a high capacitya chain expression and thus cannot develop into fully
mature effector Th1 cells (Stevens et al., 1995) (Figure 2). for endocytotic clearance and antigen presentation ac-
companied by reduced proinflammatory cytokine secre-
tion. By secreting anti-inflammatory mediators such asAlternative Activation of Dendritic Cells
IL-10, PGE2, and other molecules yet to be identified,Dendritic cells may also be alternatively activated and
alternatively activated macrophages exert immuno-may be induced to exert suppressive effects. Transfer
suppressive effects towards Th1-mediated immune re-of pancreatic lymph node dendritic cells prevents auto-
actions. In concert with special chemokines such asimmune diabetes in nonobese diabetic mice (Clare-Sal-
DC-CK1/AMAC-1, both alternatively activated macro-zler et al., 1992). Alternative activation by IL-10 inhibits
phages and dendritic cells may induce peripheral toler-tumor antigen presentation by Langerhans cells (Beis-
ance towards self-components or environmental aller-sert et al., 1995). Alternative activation by IL-10 can
gens. Thus, further clarification of alternative activationfurthermore induce cultured Langerhans cells to clonally
pathways of APC and their effector molecules may helpanergize antigen-specific Th1 cell lines, while their ac-
develop novel immunotherapeutic strategies for chroniccessory cell functions towards Th2 cell lines are pre-
inflammatory conditions including established autoim-served (Enk et al., 1993). IL-10-treated immature den-
mune and allergic diseases. To this end, it seems neces-dritic cells induce tolerance in naive T cells, and IL-10
sary to direct a major effort toward dissecting the func-induces tolerance in vivo (Steinbrink et al., 1997). In
tional and molecular repertoire of alternatively activatedaddition, untreated Langerhans cells stimulate Th1 cells,
APC and to test their integrated functions in elaboratewhile UVB-irradiated epidermal dendritic cells, similar
animal models of human disease.to UVB-induced alternatively activated macrophages,
induce Th2 cells and may mediate tolerance (Simon et
Acknowledgmentsal., 1990; Dai and Streilein, 1997).
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